MX2021014682A - Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. - Google Patents

Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.

Info

Publication number
MX2021014682A
MX2021014682A MX2021014682A MX2021014682A MX2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A
Authority
MX
Mexico
Prior art keywords
eye
protein aggregation
pharmacological agents
treating protein
aggregation diseases
Prior art date
Application number
MX2021014682A
Other languages
English (en)
Spanish (es)
Inventor
Sridhar Govinda Prasad
Marshall Clarke Peterman
Santosh Sinha
Original Assignee
Plex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plex Pharmaceuticals Inc filed Critical Plex Pharmaceuticals Inc
Publication of MX2021014682A publication Critical patent/MX2021014682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021014682A 2019-05-31 2020-06-01 Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. MX2021014682A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (1)

Publication Number Publication Date
MX2021014682A true MX2021014682A (es) 2022-04-06

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014682A MX2021014682A (es) 2019-05-31 2020-06-01 Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.

Country Status (8)

Country Link
US (1) US20220241247A1 (enExample)
EP (1) EP3976017A4 (enExample)
JP (1) JP2022534420A (enExample)
CN (1) CN114173771A (enExample)
BR (1) BR112021024151A2 (enExample)
CA (1) CA3141998A1 (enExample)
MX (1) MX2021014682A (enExample)
WO (1) WO2020243720A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512116A (ja) * 2020-01-28 2023-03-23 プロテゴ バイオファーマ， インコーポレイテッド トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2023278604A1 (en) * 2021-06-29 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2013038351A1 (en) * 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
JP6068484B2 (ja) * 2011-10-24 2017-01-25 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
BR112015021836A2 (pt) * 2013-03-08 2017-07-18 Allergan Inc conjugados de antibióticos diretamente ligados com drogas esteroides
US9789091B2 (en) * 2013-03-14 2017-10-17 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Also Published As

Publication number Publication date
WO2020243720A9 (en) 2021-02-04
EP3976017A4 (en) 2023-06-14
WO2020243720A1 (en) 2020-12-03
US20220241247A1 (en) 2022-08-04
JP2022534420A (ja) 2022-07-29
CN114173771A (zh) 2022-03-11
CA3141998A1 (en) 2020-12-03
BR112021024151A2 (pt) 2022-02-08
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
MX2020010502A (es) Agentes farmacológicos para el tratamiento de enfermedades oculares.
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
EA201000441A1 (ru) Водные офтальмологические препараты
MX360888B (es) Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.
EP4647125A3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
JP2017525769A5 (enExample)
EA201992658A1 (ru) Методы лечения рекуррентной глиобластомы (rgbm)
AU2017261303A1 (en) Ophthalmic compositions
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
BR112021024151A2 (pt) Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho
MX2021005077A (es) Peptidos y composiciones farmaceuticas para tratar enfermedades oculares.
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
JP2023099171A (ja) 緑内障を治療するためのＷｎｔ５ａの調節
MD437Y (en) Method for treating senile cataract
MX2021011727A (es) Composiciones y metodos para tratar enfermedades oculares.
BR112015023348A2 (pt) método de inibição ou reversão da progressão da formação de catarata, composição oftálmica, e, método de tratamento de uma doença relacionada ao dobramento de proteínas
EA202192928A1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
EA202193178A1 (ru) Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
ECSP20014569A (es) Métodos para el tratamiento de enfermedades relacionadas con tnf - alfa
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.